secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024139
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Q3 net loss narrows to $8.3M; Phase 2 CTI-1601 trial resumes with data expected 2H 2023
--------------------------------------------------------------------------------

- Net loss $8.3M ($0.37/share) in Q3 2022 vs $16.8M ($0.92) in Q3 2021; 9-month net loss $25.9M ($1.32) vs $41.5M ($2.48).
- Cash and marketable securities $124.7M at Sept 30, providing projected cash runway into 2H 2024.
- FDA lifted full clinical hold; Phase 2 25 mg dose exploration cohort in Friedreich's ataxia patients is ongoing; top-line data expected 2H 2023.
- Net proceeds of ~$75.2M raised in September 2022 underwritten offering; Deerfield Management participated.
- U.S. Patent No. 11,459,363 issued for CTI-1601 composition of matter, covering into July 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/0000950170-22-024139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017022024139/lrmr-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer